Trials / Completed
CompletedNCT02745769
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of ramucirumab in combination with other targeted agents in participants with advanced cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramucirumab | Administered IV |
| DRUG | Merestinib | Administered orally |
| DRUG | Abemaciclib | Administered orally |
Timeline
- Start date
- 2016-10-21
- Primary completion
- 2018-11-05
- Completion
- 2019-01-22
- First posted
- 2016-04-20
- Last updated
- 2019-03-05
Locations
5 sites across 3 countries: United States, France, United Kingdom
Source: ClinicalTrials.gov record NCT02745769. Inclusion in this directory is not an endorsement.